STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma

Metastasis frequently develops from disseminated cancer cells that remain dormant after the apparently successful treatment of a primary tumour. Prior research has shown that these disseminated populations fluctuate between an immune-evasive quiescent state and a proliferative state that is theoretically liable to immune-mediated elimination. The transition from a latent phase to an active outbreak represents a critical window where the host immune system might intervene to prevent the formation of macroscopic lesions. However, the specific molecular mechanisms that allow these cells to evade detection during their reawakening remain poorly understood in the context of lung adenocarcinoma. Clinicians currently lack effective strategies to clear these residual cells before they progress into incurable metastatic disease. This absence of evidence motivated the investigation into cancer cell-intrinsic determinants of immune reactivity during the exit from dormancy.

This research identifies specific cancer cell-intrinsic determinants that dictate immune reactivity as disseminated cells transition out of a dormant state. The investigators utilized models of indolent lung adenocarcinoma metastasis to pinpoint the molecular pathways that suppress the outbreak of secondary lesions. A primary objective involved conducting genetic screens of tumour-intrinsic immune regulators to find pathways that act as natural barriers to metastatic progression. The study specifically focused on the stimulator of interferon genes (STING) pathway to determine its role in regulating the survival of metastatic progenitors. Researchers also sought to characterize the epigenetic modifications, such as hypermethylation, that might silence these protective pathways during the formation of breakthrough metastases. The team evaluated whether systemic treatment with STING agonists could eliminate dormant metastasis and prevent spontaneous outbreaks in a T cell- and natural killer cell-dependent manner.

The experimental design utilized models of indolent lung adenocarcinoma metastasis to track the behavior of disseminated cancer cells during their transition between dormancy and proliferation. Genetic screens focused on tumour-intrinsic immune regulators were performed to identify the stimulator of interferon genes (STING) pathway as a suppressor of metastatic outbreak. Researchers monitored STING activity levels specifically within metastatic progenitors as they re-entered the cell cycle to assess temporal signaling changes. Epigenetic analysis assessed the hypermethylation of the STING promoter and enhancer regions in breakthrough metastatic sites compared to dormant cells. The study also examined chromatin repression in cells returning to dormancy under the influence of Transforming Growth Factor beta (TGFβ) signaling. Systemic treatment protocols involved administering STING agonists to mice to observe the impact on dormant metastatic populations and overall survival. The requirement for specific immune subsets was verified through depletion studies involving T cells and natural killer (NK) cells to confirm the mechanism of action.

STING pathway activity increases in metastatic progenitors that re-enter the cell cycle, functioning as a natural suppressor of metastatic outbreak. Breakthrough metastases exhibit significantly dampened STING signaling, which the researchers linked to hypermethylation of the STING promoter and enhancer sequences. Exposure to Transforming Growth Factor beta (TGFβ) induces chromatin repression that silences STING expression as cells re-enter a state of dormancy to evade immune detection. Re-expressing STING in cancer cells derived from spontaneous metastases successfully suppresses their outgrowth in experimental models. Systemic treatment of mice with STING agonists eliminates dormant metastasis and prevents spontaneous outbreaks through a coordinated immune response. These therapeutic effects are strictly dependent on the presence of functional T cells and natural killer (NK) cells within the host environment. The study confirms that these anti-metastatic effects require the intrinsic function of the STING pathway within the cancer cells themselves.

The stimulator of interferon genes (STING) pathway provides a critical checkpoint against the progression of dormant metastasis in lung adenocarcinoma. These findings suggest that the epigenetic silencing of STING through hypermethylation or chromatin repression is a key driver of metastatic relapse. Targeting this pathway with pharmacological agonists represents a therapeutically actionable strategy for the prevention of disease recurrence in patients with residual disease. The study underscores the importance of cancer cell-intrinsic immune signaling in determining the success of immune-mediated clearance during the reawakening of latent cells. Future research should explore the potential of STING-based interventions to maintain long-term dormancy or achieve complete eradication of disseminated tumour cells. This work establishes a mechanistic link between cell cycle re-entry and immune surveillance that could inform the development of next-generation cancer immunotherapies.